<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Venous thromboembolism and hormonal contraception.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Royal College of Obstetricians and Gynaecologists (RCOG). Venous thromboembolism and hormonal contraception. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2010 Jul. 13 p.&amp;nbsp;(Green-top Guideline; no. 40).&amp;nbsp; [59 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Royal College of Obstetricians and Gynaecologists (RCOG). Venous thromboembolism and hormonal contraception. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2004 Oct. 13 p. (Guideline; no. 40). [71 references]&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="HCPCS: Contraceptive supply, hormone containing vaginal ring, each "/><FieldValue Value="ICD9CM: Lupus erythematosus  (695.4); Obesity, unspecified  (278.00); Other venous embolism and thrombosis of unspecified site  (453.9); Sickle-cell disease, unspecified  (282.60); Systemic lupus erythematosus  (710.0)"/><FieldValue Value="MSH: Abortion, Induced ; Anemia, Sickle Cell ; Breast Feeding ; Contraception ; Contraceptives, Oral, Combined ; Contraceptives, Oral, Hormonal ; Counseling ; Desogestrel ; Inflammatory Bowel Diseases ; Levonorgestrel ; Lupus Erythematosus, Systemic ; Medical History Taking ; Norethindrone ; Obesity ; Postnatal Care ; Postpartum Period ; Progestins ; Risk Assessment ; Smoking ; Surgical Procedures, Operative ; Thromboembolism ; Thrombophilia ; Transdermal Patch ; Venous Thrombosis "/><FieldValue Value="MTH: Anemia, Sickle Cell ; Breast Feeding ; Combined Oral Contraceptives ; Contraception care education ; Contraception care management ; Contraceptive methods ; Counseling ; Induced abortion (procedure) ; Inflammatory Bowel Diseases ; Lupus Erythematosus ; Lupus Erythematosus, Systemic ; Norethindrone ; Obesity ; Operative Surgical Procedures ; Postpartum Period ; Progestins ; Risk Assessment ; Smoking ; Thromboembolism ; Thrombophilia ; Transdermal Patch ; Unspecified Abortion ; Venous Thrombosis "/><FieldValue Value="PDQ: obesity ; surgery ; thromboembolism "/><FieldValue Value="SNOMEDCT_US: Breast fed  (169741004); Combined oral contraceptive  (346388008); Contraception  (13197004); Contraception care education  (408968008); Contraception care management  (408969000); Contraception education  (398780007); Counseling  (129441002); Counseling  (409063005); Desogestrel  (116074007); Desogestrel  (126108008); f - Family history  (277652007); Gestodene  (395945000); Gestodene  (437760006); Inflammatory bowel disease  (24526004); Levonorgestrel  (109032009); Levonorgestrel  (126109000); Lupus erythematosus  (200936003); Norethindrone  (126102009); Norethindrone  (63758001); Obesity  (414915002); Obesity  (414916001); Postpartum  (255410009); Postpartum  (86569001); Postpartum care  (133906008); Pregnancy with abortive outcome  (363681007); Progestogen  (116614001); Progestogen  (20249007); Progestogen only oral contraceptive  (169467008); Risk assessment  (225338004); Sickling disorder due to hemoglobin S  (127040003); Sickling disorder due to hemoglobin S  (417357006); Surgical  (257556004); Surgical  (387713003); Surgical  (83578000); Systemic lupus erythematosus  (55464009); Termination of pregnancy  (386639001); Thromboembolic disorder  (13713005); Thromboembolic disorder  (371039008); Thrombophilia  (234467004); Thrombophilia  (76612001); Thrombophilia screening  (165598004); Thrombophilia screening  (314089003); Transdermal patch  (385114002); Venous thrombosis  (111293003)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Venous thromboembolism associated with hormonal contraception&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Counseling" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Family Practice" /><FieldValue Value="Hematology" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Obstetrics and Gynecology" /><FieldValue Value="Pharmacology" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To provide evidence-based recommendations and statements on association of venous thromboembolism (VTE) and hormonal contraception&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Women using hormonal contraception&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Risk Assessment/Counselling&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Assessment of medical eligibility for hormonal contraception and counselling concerning use&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Current or previous venous thromboembolism (VTE) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Family history of VTE &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Known thrombogenic mutation &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Postpartum &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Breastfeeding &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Post-abortion &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Smokers &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Obesity (body mass index of 35 kg/m&lt;sup&gt;2&lt;/sup&gt; or greater) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Surgery &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Other conditions which may predispose to venous thromboembolism (e.g., sickle cell disease, inflammatory bowel disease, systemic lupus erythematosus) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Thrombophilia screen (where indicated; not recommended routinely) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Hormonal Contraception&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Combined oral contraceptive pill &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Progestogen-only contraception (pills, injectables, implant, and intrauterine system) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Transdermal patch &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Intravaginal ring &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Absolute and relative risk of venous thromboembolism with oral contraception use&lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mortality and morbidity associated with combined oral contraceptive use&lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Health risks and benefits of hormonal contraception&lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic searches were performed for: Medline (OVID Version 1996&amp;ndash;2009), Embase (1996&amp;ndash;2009), PubMed (1996&amp;ndash;2009), the Cochrane Library (to 2009) and the U.S. National Guideline Clearinghouse. Searches were performed using relevant medical subject headings and text words. The Cochrane database was searched for systematic reviews, meta-analyses, and controlled trials relevant to venous thromboembolism and hormonal contraception. Previously existing guidelines from the Faculty of Sexual and Reproductive Healthcare (FSRH), the Royal College of Obstetricians and Gynaecologists (RCOG), and the World Health Organization (WHO) were also reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Classification of Evidence Levels&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;1++&lt;/strong&gt; High-quality meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a very low risk of bias&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;1+&lt;/strong&gt; Well-conducted meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a low risk of bias&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;1-&lt;/strong&gt; Meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a high risk of bias&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;2++&lt;/strong&gt; High-quality systematic reviews of case&amp;ndash;control or cohort studies or high-quality case&amp;ndash;control or cohort studies with a very low risk of confounding, bias or chance and a high probability that the relationship is causal&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;2+&lt;/strong&gt; Well-conducted case&amp;ndash;control or cohort studies with a low risk of confounding, bias or chance and a moderate probability that the relationship is causal&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;2-&lt;/strong&gt; Case&amp;ndash;control or cohort studies with a high risk of confounding, bias or chance and a significant risk that the relationship is not causal&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;3&lt;/strong&gt; Non-analytical studies; e.g., case reports, case series&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;4&lt;/strong&gt; Expert opinion&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Reviewing and Grading of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Once the evidence has been collated for each clinical question it needs to be appraised and reviewed (refer to section 3 in &quot;Development of RCOG Green-top guidelines: producing a clinical practice guideline&quot; for information on the formulation of the clinical questions; see the &quot;Availability of Companion Documents&quot; field). For each question, the study type with least chance of bias should be used. If available, randomised controlled trials (RCTs) of suitable size and quality should be used in preference to observational data. This may vary depending on the outcome being examined.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The level of evidence and the grade of the recommendations used in this guideline originate from the guidance by the Scottish Intercollegiate Guidelines Network (SIGN) Grading Review Group, which incorporates formal assessment of the methodological quality, quantity, consistency, and applicability of the evidence base. The methods used to appraise individual study types are available from the SIGN Web site (&lt;a href=&quot;http://www.sign.ac.uk/methodology/checklists.html&quot; title=&quot;SIGN Web site&quot;&gt;www.sign.ac.uk/methodology/checklists.html&lt;/a&gt;). An objective appraisal of study quality is essential, but paired reviewing by guideline leads may be impractical because of resource constraints.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Once evidence has been collated and appraised, it can be graded. A judgement on the quality of the evidence will be necessary using the grading system (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field). Where evidence is felt to warrant 'down-grading', for whatever reason, the rationale must be stated. Evidence judged to be of poor quality can be excluded. Any study with a high chance of bias (either 1&amp;ndash; or 2&amp;ndash;) will be excluded from the guideline and recommendations will not be based on this evidence. This prevents recommendations being based on poor-quality RCTs when higher-quality observational evidence is available.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /><FieldValue Value="Informal Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Guideline Development&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The development of guidelines involves more than the collation and reviewing of evidence. Even with high-quality data from systematic reviews of randomised controlled trials, a value judgement is needed when comparing one therapy with another. This will therefore introduce the need for consensus.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Royal College of Obstetricians and Gynaecologists (RCOG) Green-top guidelines are drafted by nominated developers, in contrast to other guideline groups such as the National Institute for Health and Clinical Excellence (NICE) and the Scottish Intercollegiate Guidelines Network (SIGN), who use larger guideline development groups. Equally, in contrast to other guideline groups, the topics chosen for development as Green-top guidelines are concise enough to allow development by a smaller group of individuals.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In agreeing the precise wording of evidence-based guideline recommendations and in developing consensus-based 'good practice points', the Guidelines Committee (GC) will employ an informal consensus approach through group discussion. In line with current methodologies, the entire development process will follow strict guidance and be both transparent and robust. The RCOG acknowledges that formal consensus methods have been described, but these require further evaluation in the context of clinical guideline development. It is envisaged that this will not detract from the rigor of the process but prevent undue delays in development.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Grades of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - At least one meta-analysis, systematic review or randomised controlled trial rated as 1++, and directly applicable to the target population; &lt;em&gt;or&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A systematic review of randomised controlled trials or a body of evidence consisting principally of studies rated as 1+, directly applicable to the target population and demonstrating overall consistency of results.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - A body of evidence including studies rated as 2++ directly applicable to the target population, and demonstrating overall consistency of results; &lt;em&gt;or&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Extrapolated evidence from studies rated as 1++ or 1+&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - A body of evidence including studies rated as 2+ directly applicable to the target population and demonstrating overall consistency of results; &lt;em&gt;or&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Extrapolated evidence from studies rated as 2++&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Evidence level 3 or 4; &lt;em&gt;or&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Extrapolated evidence from studies rated as 2+&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good Practice Point&lt;/strong&gt; - Recommended best practice based on the clinical experience of the guideline development group&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The developers reviewed published cost analyses.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Following discussion in the Guidelines Committee (GC), each Green-top guideline is formally peer reviewed. At the same time, the draft guideline is published on the Royal College of Obstetricians and Gynaecologists (RCOG) Web site for further peer discussion before final publication.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;All comments will be collated by the RCOG and tabulated for consideration by the guideline leads. Each comment will require discussion. Where comments are rejected then justification will need to be made. Following this review, the document will be updated and the GC will then review the revised draft and the table of comments.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Once the GC signs-off on the guideline, it is submitted to the Standards Board for approval before final publication.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;In addition to these evidence-based recommendations, the guideline development group also identifies points of best clinical practice in the original guideline document&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Classification of evidence levels (&lt;strong&gt;1++ to 4&lt;/strong&gt;) and grades of recommendations (&lt;strong&gt;A-D&lt;/strong&gt;) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Do Combined Hormonal Methods of Contraception (Pill, Patch and Vaginal Ring) Increase the Risk of Venous Thromboembolism?&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The relative risk of venous thromboembolism is increased with all combined hormonal contraceptives (pills, patch and vaginal ring). Nevertheless, the rarity of venous thromboembolism in women of reproductive age means that the absolute risk remains small.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The relative risk of venous thromboembolism increases in the first few months after initiating combined hormonal contraception. This risk reduces with increasing duration of use but it remains above the background risk until the combined hormonal contraceptive is stopped.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Refer to Table 1 and Table 2 in the original guideline document for information on the relative risk of venous thromboembolism for combined oral contraceptive users.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Do Progestogen-only Methods of Contraception (Pill, Injectable, Implant and Intrauterine System) Increase the Risk of Venous Thromboembolism?&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Progestogen-only pills, injectable, implants and the levonorgestrel-releasing intrauterine system do not appear to be associated with an increased risk of venous thromboembolism.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;What Conditions Which May Increase the Risk Factors of Venous Thromboembolism Are Relevant When Assessing the Medical History of Women Considering Use of Hormonal Contraception?&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Current or Previous Venous Thromboembolism&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - Women with current venous thromboembolism or previous venous thromboembolism should be advised against the use of combined hormonal contraception as this poses an unacceptable health risk.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - For women with current venous thromboembolism on anticoagulants or previous venous thromboembolism the use of progestogen-only contraception is safe.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Family History&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - The use of combined hormonal contraception by women with a family history of venous thromboembolism in a first-degree relative aged under the age of 45 years is not recommended.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Notably, some young women considering combined hormonal contraceptive use may not yet have a first-degree relative who has reached the age of 45 years to allow a relevant family history of venous thromboembolism to be excluded. A lack of exclusion should not lead to combined hormonal contraception being denied. Progestogen-only methods may be used regardless of family history.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Known Thrombogenic Mutations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - For women with a known thrombogenic mutation the use of combined hormonal contraception poses an unacceptable health risk.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Progestogen-only methods do not increase the risk of venous thromboembolism above that associated with the thrombogenic mutation itself and these methods can be used without further increasing the risk of venous thromboembolism.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Post-pregnancy Use&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - For women who are postpartum and not breastfeeding, combined hormonal contraception (pill, patch or vaginal ring) should not be initiated before day 21 postpartum.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - All hormonal contraception can be safely initiated immediately following a first- or second-trimester termination of pregnancy.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For recommendations on start times for individual progestogen-only methods in women who are postpartum and breastfeeding or not breastfeeding please see the United Kingdom Medical Eligibility Criteria for Contraceptive Use (UKMEC). In terms of venous thromboembolism risk, all hormonal methods of contraception can be commenced immediately following first- or second-trimester termination of pregnancy up to 24 weeks of gestation. &lt;strong&gt;[Evidence level 2++]&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Smoking&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - For women aged over 35 years who are current smokers or who have stopped smoking less than 1 year ago, the use of combined hormonal contraception is not recommended.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Obesity&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - For women with a body mass index of 35 kg/m&lt;sup&gt;2&lt;/sup&gt; or greater, the risks of combined hormonal contraception may outweigh the benefits.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Surgery and Other Conditions Leading to Immobilisation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Combined hormonal contraception should be discontinued and an alternative estrogen-free method used at least 4 weeks before major elective surgery where immobilisation is expected but does not need to be discontinued before minor surgery without immobilisation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A woman should be encouraged to use a method of contraception (such as progestogen-only methods) which does not increase the risk of venous thromboembolism and does not need to be discontinued before surgery. When the use of combined hormonal contraception has not been discontinued before surgery (for example, in an emergency procedure) thromboprophylaxis guidelines should be followed. This includes the use of mechanical or pharmacological thromboprophylaxis.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Is Screening for Thrombophilia Recommended before Prescribing Hormonal Contraception?&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - Routine thrombophilia screening prior to hormonal contraceptive use is not recommended.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Classification of Evidence Levels&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;1++&lt;/strong&gt; High-quality meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a very low risk of bias&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;1+&lt;/strong&gt; Well-conducted meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a low risk of bias&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;1-&lt;/strong&gt; Meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a high risk of bias&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;2++&lt;/strong&gt; High-quality systematic reviews of case&amp;ndash;control or cohort studies or high-quality case&amp;ndash;control or cohort studies with a very low risk of confounding, bias or chance and a high probability that the relationship is causal&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;2+&lt;/strong&gt; Well-conducted case&amp;ndash;control or cohort studies with a low risk of confounding, bias or chance and a moderate probability that the relationship is causal&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;2-&lt;/strong&gt; Case&amp;ndash;control or cohort studies with a high risk of confounding, bias or chance and a significant risk that the relationship is not causal&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;3&lt;/strong&gt; Non-analytical studies; e.g., case reports, case series&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;4&lt;/strong&gt; Expert opinion&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grades of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - At least one meta-analysis, systematic review or randomised controlled trial rated as 1++, and directly applicable to the target population; &lt;em&gt;or&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A systematic review of randomised controlled trials or a body of evidence consisting principally of studies rated as 1+, directly applicable to the target population and demonstrating overall consistency of results.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - A body of evidence including studies rated as 2++ directly applicable to the target population, and demonstrating overall consistency of results; &lt;em&gt;or&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Extrapolated evidence from studies rated as 1++ or 1+&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - A body of evidence including studies rated as 2+ directly applicable to the target population and demonstrating overall consistency of results; &lt;em&gt;or&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Extrapolated evidence from studies rated as 2++&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Evidence level 3 or 4; &lt;em&gt;or&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Extrapolated evidence from studies rated as 2+&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good Practice Point&lt;/strong&gt; - Recommended best practice based on the clinical experience of the guideline development group&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see &amp;quot;Major Recommendations&amp;quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Appropriate management of women using hormonal contraception to minimize the risk of venous thromboembolism&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;These recommendations are not intended to dictate an exclusive course of management or treatment. They must be evaluated with reference to individual patient needs, resources and limitations unique to the institution and variations in local populations. It is hoped that this process of local ownership will help to incorporate these guidelines into routine practice. Attention is drawn to areas of clinical uncertainty where further research may be indicated. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The Royal College of Obstetricians and Gynaecologists (RCOG) produces guidelines as an educational aid to good clinical practice. They present recognised methods and techniques of clinical practice, based on published evidence, for consideration by obstetricians and gynaecologists and other relevant health professionals. The ultimate judgement regarding a particular clinical procedure or treatment plan must be made by the doctor or other attendant in the light of clinical data presented by the patient and the diagnostic and treatment options available within the appropriate health series.&#xD;&#xA;    &lt;p&gt;This means that RCOG Guidelines are unlike protocols or guidelines issued by employers, as they are not intended to be prescriptive directions defining a single course of management. Departure from the local prescriptive protocols or guidelines should be fully documented in the patient's case notes at the time the relevant decision is taken. Once adapted for local use, these guidelines no longer represent the views of the RCOG.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Patient-centeredness" /><FieldValue Value="Safety" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Royal College of Obstetricians and Gynaecologists (RCOG). Venous thromboembolism and hormonal contraception. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2010 Jul. 13 p.&amp;nbsp;(Green-top Guideline; no. 40).&amp;nbsp; [59 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2004 Oct (revised 2010 Jul)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Royal College of Obstetricians and Gynaecologists - Medical Specialty Society" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Royal College of Obstetricians and Gynaecologists&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Guidelines Committee&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Authors&lt;/em&gt;: Dr S Brechin, MRCOG, Aberdeen; Ms JE Allerton, Somerset&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Previous Peer Reviewers&lt;/em&gt;: Dr MA Bigrigg, FRCOG, Faculty of Family Planning, Glasgow; Professor JO Drife, FRCOG, Leeds; Professor J Guillebaud, FRCOG, London; Professor P Hannaford, RCGP, Centre for General Practice, Primary Care Research and Epidemiology, University of Aberdeen; Professor KJ Pasi, Department of Haematology, Leicester Royal Infirmary; RCOG Consumers' Forum; Dr A Scott, MRCOG, Edinburgh; Dr A Szarewski, Clinical Consultant, Cancer Research UK, London&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Guideline authors are required to complete a &quot;declaration of interests&quot; form.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Royal College of Obstetricians and Gynaecologists (RCOG). Venous thromboembolism and hormonal contraception. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2004 Oct. 13 p. (Guideline; no. 40). [71 references]&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.rcog.org.uk/womens-health/clinical-guidance/venous-thromboembolism-and-hormonal-contraception-green-top-40&quot; title=&quot;RCOG Web site&quot;&gt;Royal College of Obstetricians and Gynaecologists (RCOG) Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Development of RCOG Green-top guidelines: policies and processes. Clinical Governance Advice No 1a. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2006 Nov. 6 p. Electronic copies: Available from the &lt;a href=&quot;http://www.rcog.org.uk/green-top-development&quot; title=&quot;RCOG Web site&quot;&gt;Royal College of Obstetricians and Gynaecologists (RCOG) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Development of RCOG Green-top guidelines: producing a scope. Clinical Governance Advice No 1b. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2006 Nov. 4 p. Electronic copies: Available from the &lt;a href=&quot;http://www.rcog.org.uk/womens-health/clinical-guidance/development-rcog-green-top-guidelines-producing-scope&quot; title=&quot;RCOG Web site&quot;&gt;RCOG Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Development of RCOG Green-top guidelines: producing a clinical practice guideline. Clinical Governance Advice No 1c. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2006 Nov. 13 p. Electronic copies: Available from the &lt;a href=&quot;http://www.rcog.org.uk/womens-health/clinical-guidance/development-rcog-green-top-guidelines-producing-clinical-practice-gu&quot; title=&quot;RCOG Web site&quot;&gt;RCOG Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Development of RCOG Green-top guidelines: consensus methods for adaptation of Green-top guidelines. Clinical Governance Advice No 1d. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2010 Feb. 9 p. Electronic copies: Available from the &lt;a href=&quot;http://www.rcog.org.uk/development-of-rcog-green-top-guidelines-consensus-methods&quot; title=&quot;RCOG Web site&quot;&gt;RCOG Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI on October 17, 2005. This NGC summary was completed by ECRI Institute on May 5, 2011. The updated information was verified by the guideline developer on June 3, 2011.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
